dexamethasone + cyclophosphamide + doxorubicin + granulocyte-colony stimulating factor

This is a combination chemotherapy and supportive care regimen consisting of four agents: - **Dexamethasone** is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressant properties, commonly used to reduce inflammation and as part of cancer regimens for its lympholytic effects. - **Cyclophosphamide** is an alkylating agent that crosslinks DNA, leading to cell death, particularly in rapidly dividing cells such as cancer cells. - **Doxorubicin** is an anthracycline antibiotic that intercalates into DNA, inhibits topoisomerase II, and generates free radicals, resulting in cytotoxicity against tumor cells. - **Granulocyte-colony stimulating factor (G-CSF)** stimulates the bone marrow to produce neutrophils (a type of white blood cell), reducing the risk of infection during periods of chemotherapy-induced neutropenia. This combination may be used in hematologic malignancies or solid tumors where aggressive cytotoxic therapy is indicated. G-CSF serves as supportive care to mitigate myelosuppression from the chemotherapeutic agents. The specific use case for this exact four-drug combination does not correspond to a widely recognized named protocol but represents a rational multi-agent approach combining cytotoxic drugs with growth factor support[1][2][6].